-
Azithromycin and Roxithromycin as Senolytics
2026-08-28
The 2018 study identified azithromycin and roxithromycin as clinically approved macrolide antibiotics that preferentially eliminate DNA-damage-induced senescent human fibroblasts. Its combination of selective viability screening, metabolic analysis, and real-time impedance validation provides a useful framework for studying senolytic drug repurposing while highlighting the limitations of extrapolating cell-culture findings to other antibiotic applications.
-
RIPA Lysis Buffer Strong for PDAC Protein Workflows
2026-08-28
RIPA Lysis Buffer Strong delivers powerful membrane disruption for protein extraction from pancreatic cancer cells, tissues, and macrophage models. Its inhibitor-free format lets researchers customize protection strategies for Western blotting, immunoprecipitation, ELISA, and kinase-focused workflows.
-
ARCA Cy5 EGFP mRNA (5-moUTP) Workflow
2026-08-27
Build a dual-readout workflow that separates mRNA uptake from productive translation in mammalian cells. ARCA capping, 5-methoxyuridine modification, Cy5 labeling, and EGFP expression make this reporter useful for benchmarking delivery vehicles, including lipid nanoparticle-stabilized emulsions.
-
Neuromedin S (rat): Practical Assay Guide
2026-08-27
Neuromedin S (rat) provides a defined peptide agonist for controlled neuromedin U receptor and GPCR/G protein signaling workflows. This dossier-based guide covers preparation, storage, assay controls, and troubleshooting; the reagent is for scientific research only and should not be used for diagnostic, therapeutic, or medical applications.
-
Maraviroc (UK-427857): CCR5 Beyond HIV
2026-08-26
Maraviroc is more than a CCR5 blocker for antiviral assays. This thought-leadership article connects its role in HIV-1 entry inhibition with emerging evidence on CCR5-containing extracellular vesicles, rheumatoid arthritis, neuroinflammation modulation, and translational assay design.
-
Annexin V-FITC/PI Apoptosis Assay Kit Guide
2026-08-26
The Annexin V-FITC/PI Apoptosis Assay Kit supports rapid separation of viable, early apoptotic, and membrane-compromised cell populations using phosphatidylserine binding and PI uptake. It is suitable for research flow cytometry or fluorescence microscopy, but it should not be treated as a standalone proof of apoptotic mechanism or used for diagnostic purposes.
-
Fangchinoline, TFEB, and H1N1 Lysosomal Defense
2026-08-25
The reference study identifies fangchinoline as a lysosome-targeting antiviral compound that restores TFEB-dependent lysosomal gene expression while disrupting autophagic flux and H1N1 entry. Its combined Connectivity Map, transcriptomic, cellular, and in vivo approach supports a host-directed strategy for countering influenza-associated lysosomal dysfunction.
-
Zolmitriptan: Applied 5-HT1B Workflows
2026-08-25
Build reproducible serotonin receptor assays around Zolmitriptan for migraine and cluster headache research, from solvent preparation to subtype-resolved functional readouts. The workflow also shows how recent lysosomal biology can sharpen assay controls without implying that this receptor agonist is an antiviral compound.
-
(-)-JQ1: BET Bromodomain Negative Control
2026-08-24
(-)-JQ1 is a JQ1 stereoisomer that lacks significant BET bromodomain activity and functions as an inactive control beside active (+)-JQ1. Its matched structure supports specificity testing in epigenetics research, cancer biology research, and BRD4-dependent cell line studies.
-
SARS-CoV-2 ORF3a Q57H Weakens Pro-Apoptotic Signaling
2026-08-24
The reference study shows that the SARS-CoV-2 ORF3a-Q57H variant retains similar total cellular abundance to wild-type ORF3a but is less represented at the plasma membrane and induces less apoptosis. These findings indicate that altered protein function or localization, rather than reduced whole-cell expression, may explain the variant’s weaker pro-apoptotic phenotype.
-
SNORA38B, GAB2 Signaling, and NSCLC Immunity
2026-08-23
The reference study identifies SNORA38B as an oncogenic small nucleolar RNA that connects tumor-cell signaling with an immunosuppressive microenvironment in non-small cell lung cancer. By targeting SNORA38B with locked nucleic acids, the investigators reduced tumor growth, improved cytotoxic T-cell infiltration, and increased sensitivity to immune checkpoint blockade in preclinical models.
-
Bestatin hydrochloride: Exopeptidase Study Workflows
2026-08-22
Bestatin hydrochloride, also known as Ubenimex, gives researchers a practical way to perturb aminopeptidase N/CD13 and aminopeptidase B activity across neuronal, endothelial, and tumor models. This workflow-focused guide connects the reference brain study with angiogenesis inhibition, assay design, and troubleshooting for reproducible cancer research.
-
EZH2 Inhibition and 5-AzaC in PTEN-Deficient GBM
2026-08-22
The reference study identifies suppression of the ERV–MAVS–type I interferon pathway as a mechanism of immune escape in PTEN-deficient glioblastoma. It shows that EZH2 inhibition can make 5-AzaC-mediated viral mimicry effective, providing a mechanistic rationale for combination epigenetic therapy rather than 5-AzaC monotherapy.
-
(-)-JQ1: Inactive BET Bromodomain Control
2026-08-21
(-)-JQ1 is the inactive JQ1 stereoisomer used to control BET bromodomain experiments. Its matched stereochemical relationship to active (+)-JQ1 supports specificity testing in epigenetics research, cancer biology research, and BRD4-dependent cell line studies.
-
Flubendazole for Quantitative Autophagy Assays
2026-08-20
Flubendazole enables controlled autophagy modulation research when solvent handling, exposure timing, and orthogonal viability measurements are designed together. This workflow translates cancer drug-response principles into practical assays that distinguish growth inhibition from true cell killing.